Clinical trial · Interventional
Piloting Pathways With Lung Cancer Patients
Piloting Pathways, a Hope-enhancing Intervention to Address Activity and Role Function in Metastatic Lung Cancer Patients
NCT04161157CI-TRIAL-00070210completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pathways | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Pathways
- description
- Pathways is designed to help patients identify and pursue values-based goals and address potential goal obstacles, including lung cancer stigma.
- interventionNames
- Behavioral: Pathways
Primary outcomes (2)
- measure
- Feasibility of Enrollment: Percentage of Eligible and Approached Patients Who Agree to Participate
- timeFrame
- 9 months
- description
- Percentage of eligible and approached patients who agree to participate
- measure
- Acceptability: Ratings
- timeFrame
- 9 months
- description
- Mean acceptability ratings on individual items of acceptability developed by study team (e.g., convenience of the intervention, helpfulness of the intervention, relevance of the intervention; scores of at least 7/10 on each item, possible range = 1-10, higher scores indicate higher acceptability).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * new or recurrent stage IIIB, stage IIIC or stage IV non-small cell lung cancer (NSCLC) or extensive stage SCLC * 18 years of age or older * ECOG PS 0-2/Karnofsky 60-100 * 3 to 12 weeks into active cancer treatment Exclusion Criteria: * unstable brain metastases * cognitive or psychiatric condition for which participating would be inappropriate * unable to speak and read English
References
Publications (0)
Data not yet available
No reference posted for this study.